Register entry
- Registered sites
- 0
- Active NDC listings
- 1
- Live patents
- 2
- Countries
- 0
Exclusivity
Patents and exclusivities
2| Patent | Product | Covers | Expiry |
|---|---|---|---|
| 8962680 | MYTESIcrofelemer | use | Oct 2031 |
| 9585868 | MYTESIcrofelemer | use | Oct 2031 |
Catalogue
Marketed products
1| Brand | Generic name | Form / route | NDC |
|---|---|---|---|
| MYTESI | Crofelemer | tablet, coated, oral | 70564-802NDA |
Compare
Other companies listing crofelemer
- Indena SpA2 sites · 15 NDC
Enquiry
Common questions
- Is Napo Pharmaceuticals, Inc. FDA approved?
- Napo Pharmaceuticals, Inc. holds no registered establishment of its own; 1 drug product is listed under its name in the National Drug Code Directory, made at sites registered to other firms.
- What drugs does Napo Pharmaceuticals, Inc. make?
- 1 product is listed under Napo Pharmaceuticals, Inc. in the openFDA NDC Directory, most often as tablet, coated. The full breakdown by dosage form and route is above. A listing count is not a sales figure.
Compiled from FDA establishment registrations, the openFDA NDC Directory, the Orange Book and the FDA drug shortage database. Not claimed by the company. Sources and methodology.